Misha Peter, MD
Pulmonary Disease · Bangor, MENPI 1245478239
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,761 of the $8,730 with a category attached, or 88.9%. It is spread thinly across 38 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Among pulmonary disease clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 343 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Imbed Biosciences Inc.$2K
- GSK$1K
- Inspire Medical Systems, Inc.$1K
- AstraZeneca$819
- Mylan Specialty L.p.$764
- Harmony Biosciences LLC$446
- plus $3K from 32 others
What the payments were for
- Travel & lodging$7949%
- Food & beverage$7,76189%
- Education$1752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Imbed Biosciences Inc. | 17 | $1,571 |
| GSK | 90 | $1,250 |
| Inspire Medical Systems, Inc. | 7 | $1,055 |
| AstraZeneca | 48 | $819 |
| Mylan Specialty L.p. | 36 | $764 |
| Harmony Biosciences LLC | 18 | $446 |
| Boehringer Ingelheim | 20 | $365 |
| Regeneron Healthcare Solutions, Inc. | 9 | $292 |
| Johnson & Johnson | 6 | $226 |
| ZOLL Respicardia, Inc. | 4 | $211 |
| Grifols USA, LLC | 8 | $175 |
| Jazz Pharmaceuticals Inc. | 7 | $153 |
| Amgen | 7 | $138 |
| Fisher & Paykel Healthcare Inc | 5 | $134 |
| Electromed, Inc. | 9 | $127 |
| Philips North America LLC | 7 | $121 |
| Sanofi | 5 | $107 |
| Genentech USA, Inc. | 5 | $88 |
| Gilead | 5 | $80 |
| Actelion Pharmaceuticals US, Inc. | 4 | $77 |
| United Therapeutics Corporation | 4 | $76 |
| Baxter Healthcare | 3 | $58 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| ANI Pharmaceuticals, Inc. | 1 | $40 |
| Insmed, Inc. | 2 | $40 |
| Tactile Systems Technology Inc | 2 | $39 |
| Itamar Medical Inc | 1 | $26 |
| Advanced Respiratory, Inc | 1 | $24 |
| Verona Pharma, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Resmed Corp | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,730 in reported general payments places this provider in the 90th percentile of 58 pulmonary disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pirfenidone | 12 | $107,211 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $94,192 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $11,776 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,523 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 24 | $1,355 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,247 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $1,055 |
| Montelukast Sodium | 70 | $643 |
| Zolpidem Tartrate | 18 | $166 |
| Bupropion Hcl SrBupropion Hcl | 15 | $95 |
| Gabapentin | 16 | $62 |
| Prednisone | 13 | $52 |
| Azithromycin | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,250 | $94,19297 claims |
| AstraZenecaBreztri Aerosphere | $819 | $11,77619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 58 pulmonary disease providers in Maine.
Other pulmonary disease in Bangor
- Andrew DixonBangor$40K
- Fatjon HoxhaBangor$809
- Ganesha SanthyadkaBangor$786
- Thomas RajanBangor$734
- Nabeel AlqsousBangor$624
- Sigrid NoackBangor$530
- Robert ChavkoBangor$326
- Elizabeth BollenbacherBangor$234
- Thomas FreyBangor$74
- Jonathan EvansSouth Portland$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.